GHM Multi-Drugs Rapid Test Cup US – Integrated 12-Drug Urine Screening Cup with 6 Adulterant Tests, 5-Minute Results, Customizable 2–14 Panel Configurations, and Professional Point-of-Care Use

SKU: GHM DUT-401b US
Brand: Global Healthcare Medical

Product Overview

Global Healthcare Medical GHM Multi-Drugs Rapid Test Cup US is a lateral flow chromatographic immunoassay designed for the qualitative simultaneous detection of up to 12 drugs of abuse and their metabolites, plus 6 specimen adulterant tests, in human urine specimens. The kit is intended for use by healthcare professionals as a screening test for the detection of drug abuse.

Drug abuse remains a significant global public health challenge. The World Drug Report 2024 estimates that approximately 296 million people—or 6% of the global population aged 15–64—used drugs at least once in the past year, and an estimated 64 million people worldwide suffer from drug use disorders. The global point-of-care drug of abuse testing market was valued at approximately USD 1.08 billion in 2024 and is projected to reach USD 2.45 billion by 2033, reflecting the growing demand for rapid, accessible on-site drug screening solutions. Early detection and accurate screening are critical for clinical toxicology, workplace safety, addiction treatment, and public health surveillance.

The GHM Multi-Drugs Rapid Test Cup US combines the specimen collection cup and the test device into a single integrated unit, enabling collection and testing in one convenient step. The cup accommodates 2–14 parameter options and includes 6 built-in adulterant tests to help assess specimen validity. The test utilizes a competitive binding immunoassay format, in which drugs present in the urine specimen compete with drug conjugate on the test strip for limited antibody binding sites. The result is read visually with results available at 5 minutes. This integrated cup design supports efficient, hygienic, and high-throughput screening workflows.

The GHM Multi-Drugs Rapid Test Cup US delivers qualitative results in 5 minutes, supporting rapid clinical decision-making and efficient workflow in point-of-care settings. The test is compatible with human urine specimens, providing a simple and non-invasive sample collection method suitable for a wide range of clinical and workplace settings.

The kit is intended for in vitro diagnostic use and professional use only, suitable for application scenarios including clinical toxicology laboratories, addiction treatment centers, workplace drug testing programs, emergency departments, and law enforcement agencies. The VivaDiag product line is manufactured under an EN ISO 13485 certified quality management system covering in vitro diagnostic test kits and analyzers based on immunochromatography.

Key Features & Benefits

Integrated Cup Design – Collection and Testing in One Device

The GHM Multi-Drugs Rapid Test Cup US features a self-contained cup design that integrates specimen collection and drug screening into a single device. The integrated cup format eliminates the need for separate collection containers and test devices, streamlining the testing workflow, reducing handling steps, and supporting hygienic specimen processing. The cup includes a temperature strip to verify specimen validity and a tight seal to prevent leaks during transport and testing.

Comprehensive Drug Coverage – 12 Drugs + 6 Adulterant Tests

The GHM Multi-Drugs Rapid Test Cup US is designed to simultaneously detect up to 12 drugs of abuse and their metabolites in a single urine specimen, with 2–14 parameter options available to meet specific testing requirements. The cup also includes 6 built-in adulterant tests to help assess specimen validity, supporting the integrity of the screening process. The test panel is customizable to accommodate various combinations of drug analytes.

Fast Results – 5 Minutes

The GHM Multi-Drugs Rapid Test Cup US provides qualitative results in as fast as 5 minutes, supporting rapid clinical decision-making and efficient workflow in point-of-care settings. Rapid results enable immediate on-site assessment and timely decision-making in clinical, workplace, and correctional settings.

Urine Sample Compatibility – Simple and Non-Invasive Collection

The GHM Multi-Drugs Rapid Test Cup US is compatible with human urine specimens, providing a simple and non-invasive sample collection method. The integrated cup design allows for direct collection of the urine specimen into the test cup, minimizing handling and reducing the risk of specimen contamination. The test requires only a standard urine volume for collection and testing.

Adulterant Detection – Built-in Specimen Validity Testing

The GHM Multi-Drugs Rapid Test Cup US includes 6 built-in adulterant tests to help assess specimen validity. Adulteration testing is a critical component of drug screening programs, as individuals may attempt to mask or dilute the presence of drugs in their urine. The adulterant tests evaluate parameters such as specific gravity, creatinine, pH, and oxidants. Abnormal specific gravity (below 1.003) or low creatinine levels indicate potential specimen dilution, supporting the integrity of the screening process.

Clinical Utility – Aid for Detection of Drug Abuse

The GHM Multi-Drugs Rapid Test Cup US is intended for use as a screening test for the detection of drugs of abuse and their metabolites in human urine. The test provides rapid preliminary results, enabling timely clinical decision-making and supporting patient management.

The integrated cup design provides comprehensive screening value across a wide range of commonly abused substances and specimen validity parameters. The test is particularly valuable in clinical toxicology laboratories, workplace drug testing programs, emergency departments, addiction treatment centers, and law enforcement agencies. A positive result at the specified cut-off concentration indicates a preliminary positive result and should be confirmed with a more specific alternative chemical method such as gas chromatography/mass spectrometry (GC/MS) before making clinical or employment decisions. Clinical toxicology screening informs diagnosis, guides therapeutic interventions, and aids in prognostication for poisoned or overdosed patients.

High Reliability – Trusted Clinical Performance

The GHM Multi-Drugs Rapid Test Cup US is designed to deliver reliable clinical performance with high sensitivity and specificity for all drug analytes. The test is based on the competitive binding principle, producing results that correlate with the presence or absence of the target analyte at the established cut-off level.

Performance characteristics based on product specifications and industry-standard cut-off concentrations for drugs of abuse testing. The analytical sensitivity of the test is established at the cut-off concentrations listed above. A positive result at the specified cut-off concentration indicates a preliminary positive result and should be confirmed with a more specific alternative chemical method such as GC/MS. A negative result does not rule out drug use, as the drug concentration may be below the cut-off level or the drug may no longer be detectable at the time of specimen collection. The detection window varies depending on the drug, dosage, frequency of use, and individual metabolic factors. Any visible test line, regardless of intensity, indicates a negative result, as line intensity does not correlate with drug concentration.

ISO 13485 Certified – Quality and Safety Compliance

The VivaDiag product line is manufactured under an EN ISO 13485 certified quality management system, demonstrating compliance with stringent international standards for the design, development, manufacture, and distribution of in vitro diagnostic test kits and analyzers.

CE Marked – European Conformity

The GHM Multi-Drugs Rapid Test Cup US is CE marked for professional in vitro diagnostic use, demonstrating conformity with applicable European regulatory requirements for diagnostic medical devices.

Product Specifications

Important Testing Notes:

• Collect urine specimen directly into the test cup. Do not use preservatives.

• For optimal results, test the specimen immediately after collection. If testing is delayed, refrigerate at 2–8°C. Avoid repeated freeze-thaw cycles.

• Bring all kit components and specimens to room temperature (18–30°C) prior to testing.

• Read results at 5 minutes. Do not interpret results after 10 minutes.

• A colored line in the control region (C) indicates proper test performance. A colored line in a test region (T) indicates a preliminary positive result for that drug.

• Any visible test line, regardless of intensity, indicates a negative result for that drug.

• A negative result does not rule out drug use; the drug concentration may be below the cut-off level or the drug may no longer be detectable at the time of specimen collection.

• A positive result is preliminary and must be confirmed by a more specific alternative chemical method such as GC/MS before making clinical or employment decisions.

• The adulterant tests evaluate specific gravity, creatinine, pH, and oxidants to help assess specimen validity. Abnormal specific gravity (below 1.003) or low creatinine levels indicate potential specimen dilution.

• If the control line does not appear, the result is invalid. Review the procedure and repeat with a new test.

Why Clinical Professionals Choose Global Healthcare Medical

About Global Healthcare Medical

Global Healthcare Medical is dedicated to connecting healthcare providers, retailers, and distributors with high-quality medical devices designed for reliable performance. The GHM Multi-Drugs Rapid Test Cup US is part of our professional diagnostic line, developed to support accurate, efficient, and accessible point-of-care testing in clinical environments.

Our focus is on dependable performance, clear documentation, and responsive support for professional healthcare settings.